PDN-21 in premenopausal women with systemic lupus erythematosus treated with glucocorticoids

J Rheumatol. 1995 Dec;22(12):2238-40.

Abstract

Objective: To determine if there were changes in PDN-21 and calcitonin levels in women with systemic lupus erythematosus (SLE) treated with glucocorticoids.

Methods: Concentrations of PDN-21 and calcitonin were studied in 52 premenopausal women with SLE treated with glucocorticoids. Bone mineral density analysis was performed by dual energy x-ray absorptiometry.

Results: The values of PDN-21 in the SLE group were 354.6 +/- 230.6 pg/ml, significantly higher than healthy women (66.7 +/- 56.8 pg/ml) (p < 0.001). There was no difference in calcitonin values between the SLE and control groups.

Conclusion: Glucocorticoid therapy in patients with SLE causes increases of PDN-21, probably due in part to the effect on the gastric mucosa of this treatment and subsequent secretion of gastrin.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorptiometry, Photon
  • Adult
  • Bone Density
  • Calcitonin / blood*
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Lupus Erythematosus, Systemic / blood*
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy*
  • Osteoporosis / complications
  • Osteoporosis / diagnosis
  • Osteoporosis / metabolism
  • Peptide Fragments / blood*
  • Premenopause / blood*
  • Spine / chemistry

Substances

  • Glucocorticoids
  • Peptide Fragments
  • katacalcin
  • Calcitonin